Portret photo Joost Verhaagen

Verhaagen Group

Grant from KNAW-research fund for Verhaagen group

The group of Joost Verhaagen received a grant from the KNAW-research fund (€250.000) for their research into non-invasive adeno-associated vector technology. For this project, the Verhaagen group will establish a collaborative national network, coordinated by the NIN.

The aim of the project is to generate and disseminate non-invasive adeno-associated viral vectors (AAVs), with cell selective gene targeting properties for application in a range of biomedical projects. To achieve this, the Verhaagen group will team-up with research groups at University Medical Centers/Dutch universities, Sanquin, and two other KNAW-institutes to design, create and apply non-invasive AAV vector(s) for their specific applications.

Gene delivery

Adeno-associated viral vectors (AAVs) are powerful tools for gene delivery to the brain, spinal cord and other organs. AAVs enable gene overexpression, gene editing, neural circuit modification by chemo and optogenetics, and assessment of neuronal activity. The remarkable progress that has been made in the field of gene therapy for a number of inherited and acquired diseases is due to the efficiency and safety of the AAV-vector platform. Most applications of AAV rely, however, on invasive surgical injection of the vector into the tissue of interest. Injection of AAVs only result in expression of the gene of interest in small groups of cells near the injection needle. Invasive surgical injection also can lead to bleeding, tissue damage and gliosis.

Non-invasive AAV

The Verhaagen group has a long-standing record in generating and applying AAV vectors for gene delivery to the brain. Recently, two new AAV-variants became available that allow non-invasive gene delivery to the brain or to peripheral neurons. These non-invasive AAV-variants represent a significant advance over traditional AAV vectors and, from an animal experimental point of view, these new AAV-variants are an important refinement over AAV vectors that have to be delivered by invasive surgical injection.


Mouse brain labeled with GFP
Brain of a mouse that is labeled with the reporter gene green fluorescent protein (GFP). This mouse was injected through the tail vein with a non-invasive AAV, produced by the Verhaagen group in collaboration with the lab of Viviana Gradinaru (CallTech, USA). This result forms the basis for future experiments that will be performed with the use of the received grant.
Portret photo Joost Verhaagen

Verhaagen Group

This laboratory performs basic and translational research with the aim to advance the field of restorative neuroscience and neurology. We focus on the cellular and molecular mechanisms that underlie degeneration, regeneration and plasticity of the central and peripheral nervous system. A significant portion of research is dedicated to the identification of novel genes and molecular pathways that affect the capacity of the nervous system to regenerate. Genomics, bioinformatics and high-throughput functional screening are key components of our research strategy and gene therapy based on advanced viral vector technology is applied to validate the therapeutic efficacy of molecular targets in clinically relevant animal models of neurodegeneration and repair. The ultimate goal of the Laboratory for Neuroregeneration is to develop novel therapeutic strategies to promote regeneration and plasticity of injured axons.

Read more